| SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor M Hoffmann, H Kleine-Weber, S Schroeder, N Krüger, T Herrler, ... cell 181 (2), 271-280. e8, 2020 | 22329 | 2020 |
| A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells M Hoffmann, H Kleine-Weber, S Pöhlmann Molecular cell 78 (4), 779-784. e5, 2020 | 2014 | 2020 |
| Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response I Glowacka, S Bertram, MA Müller, P Allen, E Soilleux, S Pfefferle, I Steffen, ... Journal of virology 85 (9), 4122-4134, 2011 | 1278 | 2011 |
| SARS-CoV-2 variants B. 1.351 and P. 1 escape from neutralizing antibodies M Hoffmann, P Arora, R Groß, A Seidel, BF Hörnich, AS Hahn, N Krüger, ... Cell 184 (9), 2384-2393. e12, 2021 | 998 | 2021 |
| TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein A Heurich, H Hofmann-Winkler, S Gierer, T Liepold, O Jahn, S Pöhlmann Journal of virology 88 (2), 1293-1307, 2014 | 995 | 2014 |
| Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry H Hofmann, K Pyrc, L Van Der Hoek, M Geier, B Berkhout, S Pöhlmann Proceedings of the National Academy of Sciences 102 (22), 7988-7993, 2005 | 982 | 2005 |
| The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic M Hoffmann, N Krüger, S Schulz, A Cossmann, C Rocha, A Kempf, ... Cell 185 (3), 447-456. e11, 2022 | 924 | 2022 |
| The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells M Hoffmann, H Kleine-Weber, N Krüger, M Müller, C Drosten, ... BioRxiv, 2020.01. 31.929042, 2020 | 907 | 2020 |
| Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies D Wrapp, D De Vlieger, KS Corbett, GM Torres, N Wang, W Van Breedam, ... Cell 181 (5), 1004-1015. e15, 2020 | 678 | 2020 |
| Diversity of receptors binding HIV on dendritic cell subsets SG Turville, PU Cameron, A Handley, G Lin, S Pöhlmann, RW Doms, ... Nature immunology 3 (10), 975-983, 2002 | 668 | 2002 |
| Protease inhibitors targeting coronavirus and filovirus entry Y Zhou, P Vedantham, K Lu, J Agudelo, R Carrion Jr, JW Nunneley, ... Antiviral research 116, 76-84, 2015 | 659 | 2015 |
| Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63 I Glowacka, S Bertram, P Herzog, S Pfefferle, I Steffen, MO Muench, ... Journal of virology 84 (2), 1198-1205, 2010 | 562 | 2010 |
| Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics JD Reeves, SA Gallo, N Ahmad, JL Miamidian, PE Harvey, M Sharron, ... Proceedings of the National Academy of Sciences 99 (25), 16249-16254, 2002 | 538 | 2002 |
| Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19 M Hoffmann, S Schroeder, H Kleine-Weber, MA Müller, C Drosten, ... Antimicrobial agents and chemotherapy 64 (6), 10.1128/aac. 00754-20, 2020 | 521 | 2020 |
| Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research G Simmons, P Zmora, S Gierer, A Heurich, S Pöhlmann Antiviral research 100 (3), 605-614, 2013 | 518 | 2013 |
| Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 M Hoffmann, K Mösbauer, H Hofmann-Winkler, A Kaul, H Kleine-Weber, ... Nature 585 (7826), 588-590, 2020 | 472 | 2020 |
| The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors S Pfefferle, J Schöpf, M Kögl, CC Friedel, MA Müller, J Carbajo-Lozoya, ... PLoS pathogens 7 (10), e1002331, 2011 | 463 | 2011 |
| Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts S Bertram, A Heurich, H Lavender, S Gierer, S Danisch, P Perin, ... PloS one 7 (4), e35876, 2012 | 461 | 2012 |
| DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells G Simmons, JD Reeves, CC Grogan, LH Vandenberghe, F Baribaud, ... Virology 305 (1), 115-123, 2003 | 455 | 2003 |
| DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans S Pöhlmann, EJ Soilleux, F Baribaud, GJ Leslie, LS Morris, J Trowsdale, ... Proceedings of the National Academy of Sciences 98 (5), 2670-2675, 2001 | 453 | 2001 |
